Mydecine Innovations Group, Inc.
No trades
Trade ideas
MYCO finally movingMyco finally broke out of the downward trend. I am expecting it to restest the 200ma on the daily chart.
My targets:
.32
.395
.435
Bullish PennantI can see this hitting as high as 0.69 cents a share should we break through to the upside. RSI over 50.
Mydecine Innovations Group Bull RunLT’s Comments : Let’s take a look at Mydecine Innovations Group logically and not just go crazy on what is being published out there for investors. We will go through its performance and its capability of real market price. How far can this company go?
SEC Financial Filing
Sept 30,2020
Current: $1,588,962
Total assets: $12,669,261
Total liabilities: $5,037,338
Total liabilities and shareholders’ equity: $12,669,261
December 31, 2019
Current: $601,031
Total assets: $5,288,234
Total liabilities: $231,298
Total liabilities and shareholders’ equity: $5,288,234
At September 30, 2020, the Company had not yet achieved profitable operations, has accumulated losses of $82,461,923 (December 31, 2019 - $65,069,407) since its inception and expects to incur further losses in the development of its business, all of which casts significant doubt about the Company’s ability to continue as a going concern.
LT’s Comments : Mydecine have spent, well a lot. Why? Because they believe their business model will work and achieve something great. Their advertising increased (More awareness), Consulting (Lobbyist Approval) increased and the purchase of MindLeap, etc. (Faster Clinical and Telemedicine)
Latest News: Canaccord Genuity Corp. (“Canaccord” or the “Underwriter”) pursuant to which the Company issued 34,500,000 units of the Company (the “Units”) at a price of C$0.50 per Unit (the “Issue Price”) for aggregate gross proceeds to the Company of C$17,250,000 (the “Offering”), which includes the full exercise of the overallotment option to purchase 4,500,000 Units at the Issue Price.
LT’s Comments : What is Mydecine Business Plan?
Mydecine business plan is a relatively safe one, with farms/workers already in place and already existing sale’s channels and distributors it’s a no brainer. The new acquisitions of MindLeap is a smart one since telemedicine is all the rage right now. I also believe that MindLeap was designed to speed up their clinicals for the FDA since telemedicine is now approved. With the adaption of VR/MindLeap/Game, this can definitely help the cause of anxiety and PTSD for users.
Technology
MindLeap
OS Available for both Android/IOS
LT’s Comments: Sadly, the numbers don’t lie; anxiety was already bad prior to COVID-19. It’s only getting worse and psychedelic will definitely help a lot of people.
Will Mydecine Innovations Make it?
Prior experiences say they will make it and probably end up being one of the first companies to get FDA approved psychedelics for treatment and recreational use. Why do I believe this?
Damon Michaels - Director, COO & Co-Founder
Damon Michaels is the Chief Operations Officer of Mydecine Innovations Group. Prior to joining MIG, Mr. Michaels was consulting for various hemp businesses through his company, Emerald Baron. Before that, he served as GM for the leading multi-platform cannabinoid research and technology firm based in Colorado called ebbu. In November of 2018, ebbu was acquired for CAD $429m by Canopy Growth for being the cutting edge leader in cannabinoid science. Over the last decade, Mr. Michaels has been in leading roles with multiple large brands throughout the cannabis vertical in Colorado and California. Outside of the cannabis industry, he developed a national snowboard brand with his team, was one of four entrepreneurs who created Colorado’s first-ever glass recycling company, and was on the business development team for a Google Ventures Company.
LT’s Comments: Damon’s business relationships can help with lobbyist backing, investments from large hedge funds such as Canaccord Genuity Corp (which they just recently did). Knowing the in and outs of the cannabis industry can be applied into the psychedelics industry.
Joshua Bartch - Director, CEO and Co-Founder
David Joshua Bartch is Director, President & CEO of Mydecine Innovations Group. Mr. Bartch's entrepreneurial career took off in 2009 when he co-founded AudioTranscriptionist.com and founded the Denver based dispensary, Doctors Orders. Following these ventures, Mr. Bartch founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the USA's most significant legal and sophisticated cannabis wholesale platform. In 2015, Cannabase.io was acquired by Helix TCS.
LT’s Comments: Joshua’s is definitely the guy with the vision in here and for him to bring everyone together for this project is definitely no small feat. His prior experience helps him with sales such as his sale of cannabase.io to Helix TCS. A lot of people online don’t like him because of his Facebook Public Account prior. His picture might show him as an immature younger adult during his 20s but have you ever run a few companies and sold it for a fortune? Can you bring in a guy like Damon Michaels to work with you? If not, please give this guy a chance. Look at his performance, not his old facebook photos.
Dr. Rakesh Jetly, OMM, CD, MD, FRCPC
Dr. Jetly is currently the Head of the Centre of Excellence on Mental Health in Ottawa, Ontario, and an associate professor of psychiatry at Dalhousie University (Halifax), and the University of Ottawa. He has published numerous articles in professional journals and presents nationally and internationally on such topics as post-traumatic stress disorder and operational psychiatry. Dr. Jetly has previously held various professional positions as a psychiatrist, including: Director of the “Operational Trauma and Stress Support Centre,” Atlantic Region (2000-2008); Chief Resident in Psychiatry, S͘t Michael’s Hospital (1999-2000); and Senior Medical Officer for the “Canadian Contingent United Nations Middle East” in Israel (1993-1994).
LT’s Comments: Colonel Rakesh Jetly , OMM, CD, MD, FRCPC is a BAS@$$. He is also an associate professor of psychiatry at Dalhousie University (Halifax); Queen’s University (Kingston), and the University of Ottawa. He has published numerous articles in professional journals and presents nationally and internationally on such topics as post traumatic stress disorder and operational psychiatry. Which means, this guy can get clinical done with the military and civilians.
Overall Review of Mydecine Innovations Group
With their public news of wanting to get listed in the NASDAQ, it’s very plausible for them to raise enough funds for the stock to get $3-$4 USD within a few months. We will see a bull run similar to MindMed or even more since Mydecine have the channels and prior setup necessary for the run. My price target for Mydecine is $5.00 USD.
MYCO - Next Move? MYCO has formed a prefect cup & handle on the daily
- 4 hits against an important 0.60 resistance
- handle dropped perfectly on the 0.5 fib support level
- price is currently consolidating right below resistance
Fundamentals in the psychedelic space are lining up perfectly for a MYCO breakout.
- they are 1 in only 4 companies currently approved for phase 2 FDA trials
- confirmed listing on the first ever psychedelic ETF - PSYK
However, a breakout will only be confirmed after a daily close above 0.60 - volume and a newly approved catalyst will be key
Good Luck to All!
MYCO she will be ready to pop very soonThe way I see it ....is myco should be making another run in the next couple of days heading towards the $1.10 mark, my guess is it will make it there within 2 weeks. What do you see?
MYCO climbing back up the ladder?There is evidence of a retracement. We are experiencing some resistance at $0.60. If we push past that, new targets at $0.73 and $0.90.
Assuming that MYCO is following the same kind of momentum as NUMI, I am aiming to take some profits at $2.48
strong resistance at 0.39Can legal export of 20 KG of mushrooms push MYCO past the strong resistance at 0.39? If so, the next target would be 0.50-0.58.
Trend reversal very likelyMyco has broke its wedge. While it does not necessarily fit the traditional definition I believed the circled area was a bull trap or at least just a result of shorts covering as explained by the low volume (relative) but large move up. It has been announced they will be releasing their telehealth app on sept 30th for mental health, which is an extremely big deal as telehealth is the new trend in medicine and covid resistant type businesses. If you take a look at DOC and WELL those tickers are doing extremely well.
We can very high volume kicking in So I highly doubt the green path will be followed for a retest. The orange path is more likely imo as that extreme volume indicates its a demand candle. it will likely break the larger wedge if we take a look at the other trendline.
Inverse hns + 3rd waveCurrently we are in a head and shoulders in the making with bearsih divergence and decreasing buy volume on each peak
Now if this hns matures I believe 0.3 is a logical spot for a right shoulder for a ihns it will be along the trend line and the area seems to have been a significant point horizontal S/R which coincides with .786 fib as well. Traditional SL of playing a HNS would be to use the head as a SL, but in this case that would be too Large for me to risk so ill wave for confirmation and sell if the trend line breaks. In addition it may also be the start of wave 3.
I'm looking for other bullish elevating factors as it reaches this spot such as a bullish divergence and a wedge pattern.
This may possibly reaching its fully realized target ( based on height of head) of 2.2.
